Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 5/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.41 |
| ▸ | TNK2 | Q07912 | 8/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.39 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.38 |
| ▸ | SRC | P12931 | 3/20 | 0.38 |
| ▸ | CCND1 | P24385 | 3/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | WEE1 | P30291 | 1/20 | 0.38 |
| ▸ | CCND2 | P30279 | 1/20 | 0.37 |
| ▸ | CCND3 | P30281 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035257 | 0.87 | CDK4 (0.42) | CDK4CDK6TNK2RIPK2ACVR1 | |
| SCHEMBL15035249 | 0.86 | CDK4 (0.41) | CDK4CDK6TNK2RIPK2ACVR1 | |
| SCHEMBL15035250 | 0.85 | TNK2 (0.43) | CDK4CDK6TNK2RIPK2ACVR1 | |
| SCHEMBL15035282 | 0.82 | FGFR1 (0.58) | CDK4CDK6TNK2FGFR1FGFR2 | |
| SCHEMBL15035266 | 0.82 | PAK3 (0.56) | CDK4CDK6TNK2FGFR1FGFR2 | |
| SCHEMBL15035251 | 0.78 | CDK4 (0.43) | CDK4CDK6TNK2RIPK2ACVR1 | |
| SCHEMBL15035246 | 0.77 | CDK4 (0.43) | CDK4CDK6TNK2RIPK2ACVR1 | |
| SCHEMBL15035589 | 0.77 | CDK4 (0.43) | CDK4CDK6FGFR1FGFR2FGFR4 | |
| SCHEMBL15035256 | 0.76 | PAK1 (0.42) | TNK2RIPK2NOD2 | |
| SCHEMBL15035268 | 0.76 | PAK1 (0.55) | CDK4CDK6TNK2RIPK2NOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | CDK4 404/4885CDK6 435/4885TNK2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.